VUF10166, a novel compound with differing activities at 5-HT 3A and 5-HT 3AB receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 2, 2012, Pages 350-359

  Thompson, A J ^a   Verheij, M H P ^b   De Esch, I J P ^b   Lummis, Sarah C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO (4 METHYLPIPERAZINE 1 YL)QUINOXALINE; 5 HT3AB RECEPTOR; CYSTEINE; GRANISETRON; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; VUF 10166;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELLS, CULTURED; FEMALE; GRANISETRON; HEK293 CELLS; HUMANS; ISOTOPE LABELING; LIGANDS; MUTATION; OOCYTES; PIPERIDINES; PROTEIN BINDING; QUINOXALINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; XENOPUS LAEVIS;

EID: 84859938160     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190769     Document Type: Article

References (33)

1. 3 receptor - the relationship between structure and function. Neuropharmacology 56:273-284.
2. Barrera NP, Herbert P, Henderson RM, Martin IL, and Edwardson JM (2005) Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc Natl Acad Sci USA 102:12595-12600. (Pubitemid 41266404)
3. 3B receptors. Neuropharmacology 41:282-284.
4. Das P and Dillon GH (2005) Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. J Pharmacol Exp Ther 314:320-328. (Pubitemid 41058269)
5. 3B subunit is a major determinant of serotonin-receptor function. Nature 397:359-363.
6. 3 receptor activity by an effect on the agonist-reduced desensitization. Neuropharmacology 46:192-201.
7. Drisdel RC, Sharp D, Henderson T, Hales TG, and Green WN (2008) High affinity binding of epibatidine to serotonin type 3 receptors. J Biol Chem 283:9659-9665.
8. EiseléJL, Bertrand S, Galzi JL, Devillers-Thiéry A, Changeux JP, and Bertrand D (1993) Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 366:479-483.
9. Fenster CP, Hicks JH, Beckman ML, Covernton PJ, Quick MW, and Lester RA (1999) Desensitization of nicotinic receptors in the central nervous system. Ann NY Acad Sci 868:620-623. (Pubitemid 29281174)
10. Goldin LR (1992) Maintenance of Xenopus laevis and oocyte injection, in Methods in Enzymology (Rudy B and Iverson LE eds), vol 207, pp 267-279, Academic Press, New York.
11. 3 receptors expressed in Xenopus oocytes. Neurosci Lett 247:107-110.
12. Holbrook JD, Gill CH, Zebda N, Spencer JP, Leyland R, Rance KH, Trinh H, Balmer G, Kelly FM, Yusaf SP, et al. (2009) Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 108:384-396.
13. 3receptors. Trends Pharmacol Sci 29:437-444.
14. Kawano K, Mori T, Fu L, Ito T, Niisato T, Yoshida S, Shiokawa S, Sato Y, Murakami H, and Shishikura T (2005) Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function. Neurogastroenterol Motil 17:290-301. (Pubitemid 40476691)
15. Leff P and Dougall IG (1993) Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14:110-112. (Pubitemid 23113114)
16. + channel determined by construction of multimeric cDNAs. Neuron 9:861-871.
17. 3AB receptor. Biophys J 98:1494-1502.
18. 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg Med Chem Lett 11:319-321.
19. 3receptors. Eur J Med Chem 45:4746-4760.
20. 3E. Mol Pharmacol 72:8-17.
21. Paradiso KG and Steinbach JH (2003) Nicotine is highly effective at producing desensitization of rat α4β2 neuronal nicotinic receptors. J Physiol 553:857-871. (Pubitemid 38035627)
22. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, et al. (2007) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994. (Pubitemid 46227486)
23. 3 receptor. Mol Pharmacol 80:183-190.
24. Thompson AJ, Lester HA, and Lummis SC (2010a) The structural basis of function in Cys-loop receptors. Q Rev Biophys 43:449-499.
25. Thompson AJ, Lochner M, and Lummis SC (2007) The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors. Br J Pharmacol 151:666-677. (Pubitemid 47016285)
26. 3 receptor as a therapeutic target. Expert Opin Ther Targets 11:527-540.
27. C receptors. Br J Pharmacol 153:1686-1696.
28. 3AB receptors. J. Physiol 589:4243-4257.
29. Thompson AJ, Verheij MH, Leurs R, De Esch IJ, and Lummis SC (2010b) An efficient and information-rich biochemical method design for fragment library screening on ion channels. Biotechniques 49:822-829.
30. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, et al. (2011) RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336:242-253.
31. 3 receptors: role in disease and target of drugs. Pharmacol Ther 128:146-169.
32. 3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome. J Med Chem 48:7075-7079.
33. Yu KD, Liu Q, Wu J, and Lukas RJ (2009) Kinetics of desensitization and recovery from desensitization for human α4β2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells. Acta Pharmacol Sin 30:805-817.